SecBot SecBot
Biotech Drug Report Generated Nov 13, 2026

ulixacaltamide

PRAX·Praxis Precision Medicines, Inc.
BULLISH
Drug Impact Rating8/10
Trial phase
Filed/NDA under FDA review (PDUFA January 29, 2027)
Time to market
If approved, launch is anticipated in early 2027, shortly after the January 29, 2027 PDUFA date.
Why 8/10
The next hard, dated catalyst is the FDA PDUFA target action date of January 29, 2027, roughly 2.5 months from today. Ulixacaltamide is Praxis's lead asset, driving approximately 70% of the company's modeled pipeline value, and the PDUFA represents a binary approval/rejection decision in a large unmet-need market with no currently approved targeted pharmacotherapy.
Actionable Insight BULLISH

The next hard catalyst is the PDUFA decision on January 29, 2027, roughly 2.5 months away. An approval would make ulixacaltamide the first FDA-approved targeted pharmacotherapy for essential tremor, a large unmet-need market. A Complete Response Letter would erase most of the company's modeled value. Watch for any FDA AdComm announcement (none currently expected) and for the relutrigine PDUFA on December 27, 2026, which will set the tone for the stock ahead of the ulixacaltamide decision.

Price Chart

Loading chart...

Executive Summary

Ulixacaltamide is Praxis Precision Medicines' lead drug candidate, an oral T-type calcium channel antagonist for essential tremor, a movement disorder affecting roughly 7 million Americans with no currently approved targeted pharmacotherapy. Positive Phase 3 Essential3 topline results were announced in October 2025, driving the stock up over 200%. The FDA accepted the NDA in April 2026 with a PDUFA target action date of January 29, 2027, and granted Breakthrough Therapy Designation. No advisory committee meeting is currently expected. The stock trades around $321 with a Strong Buy analyst consensus and a mean price target of $662, implying roughly 106% upside. However, the stock is highly concentrated on this single binary catalyst (about 70% of modeled pipeline value), and tolerability issues from the Phase 3 data pose commercial risk.

How It Works

Ulixacaltamide is an oral medication that blocks T-type calcium channels in the brain. These channels are involved in generating the abnormal rhythmic electrical activity that causes essential tremor (uncontrollable shaking, typically of the hands). By blocking them, the drug aims to reduce tremor severity and improve patients' ability to perform daily activities like eating, writing, and drinking.

Trial Status

Two pivotal Phase 3 Essential3 studies completed with positive topline results (both met primary endpoint mADL11 at Week 8 with p<0.0001). NDA submitted in early 2026 and accepted by FDA in April 2026. Breakthrough Therapy Designation granted December 2025. A transdermal formulation is also in early development via a collaboration with Remagine Labs.

The Two-Sided Case

▲ Bull Case6
Positive Phase 3 Essential3 program: Both pivotal studies met their primary endpoint (mADL11 at Week 8) with statistical significance (p<0.0001), showing clinically meaningful improvement in daily function.
First-to-market opportunity: No FDA-approved targeted pharmacotherapy currently exists for essential tremor, which affects approximately 7 million Americans. Ulixacaltamide would be the first.
FDA Breakthrough Therapy Designation (December 2025) signals agency engagement and supports a streamlined review; no advisory committee meeting is currently expected.
Strong analyst support: Consensus is Strong Buy (24 Buy/Strong Buy vs 2 Hold and 1 Strong Sell), with a mean price target of $661.75, implying ~106% upside from the current ~$321 price.
Institutional accumulation: Q3 2026 13F filings showed broad institutional buying, with multiple funds adding or doubling positions (Franklin Templeton, Jane Street, Jupiter Asset Management, Westfield Capital).
Lifecycle expansion: Praxis partnered with Remagine Labs in July 2026 to develop a transdermal formulation, potentially expanding the addressable patient population beyond the initial oral capsule.
▼ Bear Case5
Tolerability concerns: Phase 3 data showed high adverse event-related discontinuation rates, which could limit commercial uptake or prompt FDA labeling restrictions.
Competition emerging: Acurex Biosciences received a composition-of-matter patent for CU-00048, another oral T-type calcium channel antagonist for essential tremor, and non-drug wearables like Encora X1 are already FDA-cleared.
Premium valuation: At ~$321/share, the stock already prices in substantial approval and commercial success; a Seeking Alpha analysis in June 2026 estimated fair value at $223.73, calling the premium 'unrealistic.'
Concentration risk: Approximately 70% of Praxis's modeled pipeline value depends on ulixacaltamide approval, making the stock highly binary at the PDUFA date.
The company also has a second NDA (relutrigine) under FDA review with a December 27, 2026 PDUFA; a negative outcome there could spill over into sentiment on ulixacaltamide.

Upcoming Catalysts

  • PDUFA target action date: January 29, 2027 (FDA decision on approval)
  • Relutrigine PDUFA: December 27, 2026 (sister drug, could affect sentiment)
  • Potential FDA advisory committee meeting (none currently expected, but could be scheduled)
  • Commercial launch preparations and Investor Day (November 12, 2026 already held)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Praxis Precision Medicines, Inc. 8-K PRAX ·Originating report

Sources · 11

Hover a chip for the title
1 marketscreener.com2 markets.businessinsider.com3 empr.com4 finanznachrichten.de5 nasdaq.com6 empr.com7 nasdaq.com8 prnewswire.com9 seekingalpha.com10 seekingalpha.com11 seekingalpha.com